TRACON Pharmaceuticals Inc (TCON) Cotización

TCON: effective Dec. 3,2024: Charter Cancelled/Dissolution

FINRA will delete the symbol.

https://otce.finra.org/otce/dailyList?viewType=Deletions

Layoffs, Liquidation.

https://www.globenewswire.com/news-release/2024/07/01/2906758/10391/en/TRACON-Pharmaceuticals-Announces-Termination-of-ENVASARC-Trial-and-Will-Explore-Strategic-Alternatives-Leveraging-its-In-House-Product-Development-Platform.html

TCON delisted from the Nasdaq to the OTC. PPS dropped from $1.77 to $1.09

https://otce.finra.org/otce/dailyList?viewType=Additions

TCON new 52 week low

Old

TCON under $2

TCON: effective April 10,2024 a one for 20 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

ya thats my thought too. Thanks, all the best

I liquidated my position in TCON on the news. I don't see a path forward for TCON that is good for current shareholders. I will monitor TCON going forward from the sidelines.

Hi Tartia,
I have no idea how this is possible. I guess its dead now. What do you think?

With a float of 26 million shares and a market cap of $23 million, TRACON operates within the realm of oncology research and development. Envafolimab, one of TRACON’s key assets, has garnered both Fast Track Designation and Orphan Drug Designation. Envafolimab, a novel PD-L1 antibody, is administered via subcutaneous injection, offering a convenient treatment approach.

The pivotal Phase 3 trial for Envafolimab, known as ENVASARC, is anticipated to provide updated safety and efficacy data by the end of the first quarter of 2024, with final data expected in the second half of the same year. The study design, presented at the American Society of Clinical Oncology (ASCO) in the previous year, outlines primary endpoints focused on objective response rate (ORR) confirmed by independent central review. The trial aims to assess Envafolimab’s efficacy, particularly in refractory undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) patients, with an ORR confirmed by BICR with 9/80 objective responses needed to exclude the known < 5% ORR of pazopanib, the only agent approved for patients with refractory UPS or MFS.

TCON..................................https://stockcharts.com/h-sc/ui?s=TCON&p=W&b=5&g=0&id=p86431144783

$TCON Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z

TCON $0.25 -interin data readout coming within days - market cap only $10 million

TCON $0.24 with buy rating check out link below
https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png

Nice to see these Pharmaceuticals go up today!
TCON up 15.38% regular trading close
JAGX hit .1362 in after hours, up from .1027 open
ATNM up 2.95%

52 week highs:
TCON $2.19
JAGX $5.08
ATNM $14.70

I only own AMRN and JAGX as my small cap ones. But am watching Tracon as I think they will get another order like the previous one that shot them up.

TCON needs to be over $1.124 by March 7th

To do that there has to be some good exciting news releases from now and then. The news would have to be so good that shorts would all want to cover.
The higher the stock runs the better chance it stays on NASDAQ

A reverse split is not going to get it there because there would be too few of outstanding shares.



As previously reported, on June 8, 2023, TRACON Pharmaceuticals, Inc. (the “Company”) received notices (the “Notices”) from Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that (i) for 30 consecutive business days preceding the date of the Notices, the market value of the Company’s common stock was less than $35.0 million, which does not meet the requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Market Value Rule”) and the Company did not meet any of the alternative continued listing requirements set forth in Nasdaq Listing Rule 5550(b) (the “Financial and Liquidity Standards”), and (ii) for 30 consecutive business days preceding the date of the Notices, the closing bid price of the Company’s common stock was below $1.00 per share, which is the minimum required closing bid price for continued listing on the Nasdaq Capital Market pursuant to Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company was provided 180 calendar days, or until December 5, 2023, to regain compliance with one of the Financial and Liquidity Standards and the Minimum Bid Price Requirement.

On December 12, 2023, the Company submitted a request for an oral appeal hearing before a Hearings Panel (the “Panel”). The hearing is scheduled to occur on March 7, 2024. Accordingly, the delisting and suspension of trading of the Company’s common stock described in the December 6 Notice will be stayed pending the issuance of the Panel’s final written decision. There can be no assurance that a favorable decision will be obtained from the Panel or that the Company will be successful in maintaining the listing of its common stock on the Nasdaq Capital Market.

TJ are you out of all stocks now?
I was just looking back at the old 8k's here.
I think this may have a chance for some news soon and maybe another spike but what do i know?
I can't predict news............

But the pre market has ended and the open market is not that impressed...

Big news out having a great pre market day

Nice day so far hopefully it holds these gains

Thats the goal... get settled back in at a dollar and then let all hell break loses...

It would be nice to see this get over $1

Yes, thanks. Good luck to us

Closed at .21 in after hours hopefully some news drops tomorrow. Nice buy you have as well. Another 3 million dollar contract drops and this will move by leaps and bounds.

Still have my shares I bought at $0.185 last week. Nice action today!

Hell of a lot of ASK slapping today.... raise your hand if you joined me in buying those17 at the end of last week and the start of this week... The rest of you just grab a Puffs Plus

Market it still creating a buying opp, there are a lot of folks that have not read the 8-K on this last $3,000,000.00 up front payment deal... a $20 a share Pharma company is not small potatoes and for them to want this product speaks volumes. Lots more to come based on just this one deal. So thanks for the cheapies who ever it was that pushed this down to the 17's


https://ih.advfn.com/stock-market/NASDAQ/tracon-pharmaceuticals-TCON/stock-news/92608567/form-8-k-current-report

TJ.. i posted this yesterday on another board
We bought TCON in hopes to make a profit.
I bought as high as .3089 and as low as .1862
I am not worried i am just waiting for the fluctuations. TCON is now heavily shorted.
They will have to buy back shares.

Tracon the company said it has licensed its proprietary PDP of CRO-independent clinical research to a clinical-stage biotech firm for a $3M upfront payment.

Latest news with Inhibrix is a big deal.

Under the deal, TRACON granted a non-exclusive and non-transferable license of its PDP to the clinical-stage biotech company for the design, conduct, and administration of clinical trials and related research and development activities, among others.
“We are now in a position to widely license our PDP to allow clinical-stage biotechnology and pharmaceutical companies to transform their clinical operations with the expectation of potentially dramatic cost reductions and shorter clinical trial timelines,” said CEO Charles Theuer.

About Inhibrix
Ticker INBX $20.54
$337 million in cash, so they have the money for the $3 Million deal.

https://inhibrx.com/wp-content/uploads/2023/11/Inhibrx-Presentation-Nov-2023.pdf

On November 17, 2023 (the “Effective Date”), Tracon Pharmaceuticals, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Inhibrx, Inc. (“Inhibrx”). Under the terms of the Agreement, the Company granted a non-exclusive and non-transferable license of its product development platform to Inhibrx for the design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals (the “Tracon PDP License”). The Tracon PDP License will allow Inhibrx to use the Company’s configuration documentation with a widely used software package in addition to use of the Company’s validation and qualification of the software package, and the Company’s standard operation procedure documents, policies, work instructions, and clinical operation templates (the “Licensed Technology”). Upon Inhibrx’s request during the first six months after the Effective Date, the Company is obligated to provide up to 500 hours of training (“Technical Support”) to Inhibrx. Pursuant to the Agreement, Inhibrx will make an upfront payment of $3.0 million to the Company, plus a potential $0.2 million (i) upon the completion of the Technical Support by the Company, or (ii) six months following the Company’s delivery of the Licensed Technology, whichever is earlier.

Thanks for the info

Not sure how many have seen the 8 K that was filed to go along with the PR on the $3,000,000 contract but this is the company that bought the PDL licensee from TRACON Pharmaceuticals Inc. They are a $20.00 a share NASDAQ stock. This is not a micro cap Pinksheet stock its a $900 million dollar market cap company.

https://ih.advfn.com/stock-market/NASDAQ/tracon-pharmaceuticals-TCON/stock-news/92608567/form-8-k-current-report

https://inhibrx.com/investors/

Charles will split and dilute. He’s a pos.

I just bought more before after market close.
Never know which direction this could go from here.
To cheap at this level.

Good thing about Etrade is you can put a pre market order in and it will stall all day and up till 8 pm if you so choose...

I had a buy order in the 17's in the AM market and I wasn't following it and the order automatically expired when the regular market opened

Some Thanksgiving selling, very typical with this level of stocks...also a very nice buying opp for those that can see past two or three days in advance... doubled my holdings in those 17's which was just where my original buy in was.

The 8am had a little spike and pulled back.
I am not worried about price decline.
It tends to pop later or another day.

Well pre market is not doing us any favors down over 2 cents so far and we have yet to hit the real premarket trading which starts at 8 am

Most likely are good buying opp will come out of this morning

Lots of vol pre-mkt,could see gap up if hc wainwright paid promo shares are finally gone,(that analyst co is horrible,they shouldn’t be able to call themselves analysts,all they do is put $7 on everything and get tons of shares and dump them until gone)

Yes, it looks promising!

A lot in the pipeline: "TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The Company offers partners a solution for the clinical development and commercialization of their products in the United States."
smile

Volume(Heavy Day) 73,872,965 November 21, 2023 3:59pm ET

$15m traded today,gaining enough interest to have a sleepover for me

Big orders slapping,some $15k,inst./whales?,gotta love big solid green candles as power hour approaches

30% institutional,inst. controls 80% of entire mkt moves.follow the $ is a saying for a good reason.I doubt the blackrock crooked mms gonna destroy this,I could be wrong but it is optionable,contracts can suck for retail,holding up great so far and huge short to cover yet.support yesterday was sma200(5min) currently.1834 we getting close now

7m cash on hand,only 1m debt,no offering needed,1st of many contracts,3m contract on a 5m mkt cap,adjustment inbound,pps headed over $1 so no r/s needed.

TCON biz model is genius,during a gold rush sell pics/axes/shovels/maps/teach ppl how to pan,guarantee $ in bank!!

Expect mid day vol surge soon